NO20042227L - a-form eller Β-form-krystall av acetanilid-derivat - Google Patents

a-form eller Β-form-krystall av acetanilid-derivat

Info

Publication number
NO20042227L
NO20042227L NO20042227A NO20042227A NO20042227L NO 20042227 L NO20042227 L NO 20042227L NO 20042227 A NO20042227 A NO 20042227A NO 20042227 A NO20042227 A NO 20042227A NO 20042227 L NO20042227 L NO 20042227L
Authority
NO
Norway
Prior art keywords
crystal
acetanilide derivative
acetanilide
derivative
form crystal
Prior art date
Application number
NO20042227A
Other languages
English (en)
Other versions
NO326965B1 (no
Inventor
Takayuki Suzuki
Tatsuya Maruyama
Kenichi Onda
Souichirou Kawazoe
Kenichirou Sakamoto
Yuji Awamura
Toshiyuki Takasu
Original Assignee
Yamanouchi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19148268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20042227(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd
Publication of NO20042227L publication Critical patent/NO20042227L/no
Publication of NO326965B1 publication Critical patent/NO326965B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
NO20042227A 2001-10-30 2004-05-28 a-form eller β-form-krystall av acetanilid-derivat og farmasoytisk preparat NO326965B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001332914 2001-10-30
PCT/JP2002/011217 WO2003037881A1 (fr) 2001-10-30 2002-10-29 Cristal a forme $g(a) ou $g(b) d'un derive acetanilinide

Publications (2)

Publication Number Publication Date
NO20042227L true NO20042227L (no) 2004-05-28
NO326965B1 NO326965B1 (no) 2009-03-23

Family

ID=19148268

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042227A NO326965B1 (no) 2001-10-30 2004-05-28 a-form eller β-form-krystall av acetanilid-derivat og farmasoytisk preparat

Country Status (17)

Country Link
US (2) US7342117B2 (no)
EP (3) EP1932838A3 (no)
JP (1) JP3800220B2 (no)
KR (1) KR100908796B1 (no)
CN (1) CN1243740C (no)
AU (1) AU2002344419C1 (no)
BR (1) BRPI0213570B8 (no)
CA (1) CA2464068C (no)
ES (1) ES2404071T3 (no)
HU (1) HU230481B1 (no)
MX (1) MXPA04003936A (no)
NO (1) NO326965B1 (no)
PL (1) PL218982B1 (no)
RU (1) RU2303033C2 (no)
TW (1) TW200300020A (no)
WO (1) WO2003037881A1 (no)
ZA (1) ZA200403044B (no)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342117B2 (en) * 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
PL211687B1 (pl) 2002-11-07 2012-06-29 Astellas Pharma Inc Środek leczniczy przeznaczony do leczenia nadmiernie aktywnego pęcherza moczowego, zawierający jako składnik aktywny pochodną acetanilidu
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
PL2216021T3 (pl) * 2007-11-02 2013-03-29 Astellas Pharma Inc Kompozycja farmaceutyczna do leczenia zespołu pęcherza nadreaktywnego
JP2011522828A (ja) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
AU2009307884B2 (en) 2008-10-22 2014-07-31 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US8586760B2 (en) 2009-06-15 2013-11-19 Auspex Pharmaceuticals, Inc. Aminothiazole modulators of beta-3-adrenoreceptor
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
TR201802207T4 (tr) 2010-03-29 2018-03-21 Astellas Pharma Inc Kontrollü Salımlı Farmasötik Bileşim.
ES2524896T3 (es) * 2010-06-16 2014-12-15 Takeda Pharmaceutical Company Limited Cristal de compuesto de amida
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN105001219A (zh) 2011-02-25 2015-10-28 默沙东公司 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
WO2012156998A2 (en) * 2011-05-18 2012-11-22 Dr. Reddy's Laboratories Limited Amorphous mirabegron and processes for crystal forms of mirabegron
US9655885B2 (en) 2011-05-18 2017-05-23 Dr. Reddy's Laboratories Ltd. Amorphous mirabegron and processes for crystal forms of mirabegron
WO2013147134A1 (ja) 2012-03-30 2013-10-03 アステラス製薬株式会社 ミラベグロン含有医薬組成物
CN103387500A (zh) * 2012-05-11 2013-11-13 上海医药工业研究院 一种米拉贝隆及其中间体的制备方法
KR20150036245A (ko) 2012-08-02 2015-04-07 머크 샤프 앤드 돔 코포레이션 항당뇨병 트리시클릭 화합물
CN104602693A (zh) 2012-08-31 2015-05-06 安斯泰来制药株式会社 口服给药用药物组合物
BR112015019836A2 (pt) 2013-02-22 2017-07-18 Merck Sharp & Dohme composto, composição farmacêutica, e, uso de um composto
WO2014132270A2 (en) * 2013-02-27 2014-09-04 Msn Laboratories Limited Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
CN103193730A (zh) * 2013-04-17 2013-07-10 苏州永健生物医药有限公司 一种米拉贝隆的合成方法
CN103232368B (zh) * 2013-04-18 2015-08-12 苏州永健生物医药有限公司 一种(r)-4-硝基苯乙基-(2-羟基-2-苯乙基)-氨基甲酸叔丁酯的合成方法
CN103232352B (zh) * 2013-05-11 2015-12-23 苏州永健生物医药有限公司 (r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
WO2015040605A1 (en) 2013-09-23 2015-03-26 Ranbaxy Laboratories Limited Crystalline form of mirabegron
WO2015040573A1 (en) 2013-09-23 2015-03-26 Ranbaxy Laboratories Limited Mirabegron dimethyl sulphoxide solvate and its use for the treatment of overactive bladder
WO2015044965A1 (en) 2013-09-30 2015-04-02 Megafine Pharma (P) Ltd. A process for preparation of mirabegron and alpha crystalline form thereof
ITMI20131653A1 (it) 2013-10-07 2015-04-08 Dipharma Francis Srl Forme cristalline di un agonista adrenergico
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN103641792B (zh) * 2013-12-27 2015-07-22 国药集团国瑞药业有限公司 一种米拉贝隆有关物质或其盐、其制备方法和用途
CN104876889B (zh) * 2014-02-27 2017-02-22 人福医药集团股份公司 化合物的合成方法
WO2015155664A1 (en) * 2014-04-08 2015-10-15 Suven Life Sciences Limited An improved process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-[[(2r)-2-hydroxy-2- phenylethyl]amino]-ethyl)phenyl]acetamide
CN103896872A (zh) * 2014-04-29 2014-07-02 黑龙江大学 米拉贝隆的合成方法
CN104016943A (zh) * 2014-05-23 2014-09-03 苏州凯瑞医药科技有限公司 一种米拉贝隆的合成方法
CN104016877B (zh) * 2014-06-13 2017-02-15 南京海融制药有限公司 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用
ES2676586T3 (es) * 2014-08-06 2018-07-23 Interquim, S.A. Procedimiento para la síntesis de mirabegron y sus derivados
WO2016024284A2 (en) 2014-08-07 2016-02-18 Wanbury Ltd. A process for the preparation of mirabegron and its intermediates
CN105481705A (zh) * 2014-08-23 2016-04-13 南京海纳医药科技有限公司 (r)-2-[[2-(4-氨基苯基)乙基]氨基]-1-苯乙醇的制备及应用
CN104230840A (zh) * 2014-09-05 2014-12-24 安徽联创药物化学有限公司 米拉贝隆的合成方法
WO2016046763A1 (en) * 2014-09-26 2016-03-31 Universita' Degli Studi Di Bari Selective agonists of beta-adrenergic type 3 receptors (bar3) and use thereof
WO2016049749A1 (en) * 2014-10-01 2016-04-07 Apotex Inc. Solid forms of mirabegron
EP3253741A1 (en) 2015-02-02 2017-12-13 Lupin Limited Process for preparation of polymorphic form of mirabegron
JP2018090490A (ja) 2015-03-31 2018-06-14 アステラス製薬株式会社 ミラベグロン含有医薬組成物
FR3043555B1 (fr) * 2015-11-17 2019-10-25 Centre National De La Recherche Scientifique (Cnrs) Mirabegron pour le traitement de maladies retiniennes
EP3184516A1 (en) 2015-12-23 2017-06-28 Enantia, S.L. Crystalline inclusion complexes of mirabegron with beta-cyclodextrin
CN105801438A (zh) * 2016-04-12 2016-07-27 济南大学 一种米拉贝隆中间体的合成方法
CN107963976A (zh) * 2016-10-20 2018-04-27 中国动物疫病预防控制中心 一种苯乙醇胺类化合物中间体的制备方法
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
EP3489224A1 (en) 2017-02-14 2019-05-29 Alfred E. Tiefenbacher (GmbH & Co. KG) Mirabegron prodrugs
KR101868438B1 (ko) 2017-04-13 2018-06-20 (주) 성운파마코피아 아미드 유도체의 제조방법
AU2018282104B2 (en) 2017-06-06 2024-07-11 Urovant Sciences Gmbh Use of vibegron to treat overactive bladder
KR102398639B1 (ko) 2017-06-20 2022-05-17 (주) 성운파마코피아 아미드 유도체의 염 및 그 제조방법
CN108658797A (zh) * 2018-06-19 2018-10-16 安徽德信佳生物医药有限公司 一种米拉贝隆中间体(r)-2-(4-硝基苯乙基氨基)-1-苯基乙醇盐酸盐的合成
CN108947853A (zh) * 2018-06-29 2018-12-07 黑龙江鑫创生物科技开发有限公司 一种微通道反应器合成米拉贝隆中间体的方法
KR101928987B1 (ko) * 2018-08-28 2018-12-13 (주) 성운파마코피아 신규한 고순도 미라베그론의 결정질 일수화물, 이의 제조방법 또는 용도
KR20200117091A (ko) 2019-04-02 2020-10-14 제이투에이치바이오텍 (주) 미라베그론 전구체 약물 화합물 및 이의 과민성 방광 질환의 치료 또는 개선을 위한 의약 용도
CN110590699B (zh) * 2019-09-29 2022-11-15 广东先强药业有限公司 一种米拉贝隆的精制方法
EP3722285B1 (en) 2020-04-08 2022-03-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Process for preparing mirabegron enacarbil
CN113816864B (zh) * 2020-06-18 2024-03-29 南京正大天晴制药有限公司 一种(r)-2-羟基-n-[2-(4-氨基苯基)乙基]-2-苯乙胺的制备方法
CN114539182B (zh) * 2020-11-24 2024-08-09 威智医药股份有限公司 转晶溶剂及其应用和米拉贝隆α晶型的制备方法
CN114539084B (zh) * 2020-11-24 2024-04-02 威智医药股份有限公司 米拉贝隆及其中间体的制备方法
KR20220081033A (ko) 2020-12-08 2022-06-15 주식회사 한서켐 미라베그론 α형 결정의 제조방법
CN112574137A (zh) * 2021-01-19 2021-03-30 南京美瑞制药有限公司 一种α晶型米拉贝隆的制备方法
KR20240116208A (ko) 2023-01-20 2024-07-29 이니스트에스티 주식회사 결정형의 미라베그론 신규염, 이의 제조방법 및 이를 포함하는 약학적 조성물
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1921577B2 (de) * 1969-04-28 1972-04-06 Nixdorf Computer Ag, 4790 Paderborn Trommelartige vorrichtung zn buchungs- und schreibautomaten mit greifeinrichtung zum erfassen und einziehen von kontokarten o dgl
JPH02279685A (ja) 1989-04-18 1990-11-15 Yoshitomi Pharmaceut Ind Ltd 新規な結晶構造を有するチアジアジン化合物およびその製造法
PT1028111E (pt) * 1997-10-17 2004-09-30 Yamanouchi Pharma Co Ltd Derivados de amida ou seus sais
JP3901832B2 (ja) 1998-03-13 2007-04-04 大日本インキ化学工業株式会社 キノリノン誘導体製剤、及びその製造法
JP2000212168A (ja) 1999-01-22 2000-08-02 Yamanouchi Pharmaceut Co Ltd ヘキサヒドロ―１，４―ジアゼピン誘導体塩水和物の新規結晶
CA2349663C (en) * 1999-09-10 2006-10-31 Dainippon Ink And Chemicals, Inc. Quinolinone derivative formulation and its production method
US6706733B2 (en) * 2001-05-08 2004-03-16 Dainippon Ink And Chemicals, Inc. Quinolinone derivative formulation and its production method
US7342117B2 (en) * 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative

Also Published As

Publication number Publication date
KR20050040837A (ko) 2005-05-03
US20050004190A1 (en) 2005-01-06
US7982049B2 (en) 2011-07-19
PL369874A1 (en) 2005-05-02
NO326965B1 (no) 2009-03-23
EP1932838A2 (en) 2008-06-18
US7342117B2 (en) 2008-03-11
KR100908796B1 (ko) 2009-07-22
EP1932838A3 (en) 2008-07-30
PL218982B1 (pl) 2015-02-27
RU2303033C2 (ru) 2007-07-20
MXPA04003936A (es) 2004-06-18
HUP0401665A1 (hu) 2004-11-29
HU230481B1 (hu) 2016-07-28
BRPI0213570B8 (pt) 2021-05-25
EP2298752B1 (en) 2013-03-27
CN1575287A (zh) 2005-02-02
BR0213570A (pt) 2004-10-26
US20080214633A1 (en) 2008-09-04
CA2464068A1 (en) 2003-05-08
CA2464068C (en) 2007-10-16
JP3800220B2 (ja) 2006-07-26
ZA200403044B (en) 2005-06-29
EP1440969A4 (en) 2005-01-19
KR100908796B9 (ko) 2024-07-17
JPWO2003037881A1 (ja) 2005-02-17
BRPI0213570B1 (pt) 2018-02-27
EP1440969A1 (en) 2004-07-28
EP2298752A1 (en) 2011-03-23
AU2002344419C1 (en) 2024-02-01
WO2003037881A1 (fr) 2003-05-08
CN1243740C (zh) 2006-03-01
AU2002344419B2 (en) 2007-12-13
ES2404071T3 (es) 2013-05-23
HUP0401665A3 (en) 2008-05-28
TWI322805B (no) 2010-04-01
RU2004116313A (ru) 2005-03-27
TW200300020A (en) 2003-05-01

Similar Documents

Publication Publication Date Title
NO20042227L (no) a-form eller Β-form-krystall av acetanilid-derivat
AU2002344419A1 (en) Alpha-form or beta-form cyrstal of acetanilide derivative
NO20035177D0 (no) Krystallformer av Azithromycin
DK1432408T3 (da) Farmaceutiske sammensætninger indeholdende kolloidt siliciumdioxid
DE50004212D1 (de) Wasserbasierende Zusammensetzung aminofunktioneller Siliciumverbindungen
NO20042680L (no) Fremgangsmater for fremstilling av O-demetylvenflaxine
NO20042842L (no) Farmasoytiske formuleringer av platina-derivat
NO20043110L (no) Direkte komprimerbare formuleringer av azitromycin
ATE349431T1 (de) Herstellung von aminopyrimidinverbindungen
DE60218175D1 (de) Stabilisierte orale suspensionsformulierung
NO20024386D0 (no) Farmasöytiske sammensetninger av glycogenfosforylase- inhibitorer
CY2009001I2 (el) Νεα μορφη κρυσταλλου του παραγωγου πυρρολιδυλοθειοκαρβαπενεμης
NO20014256D0 (no) Fremstilling av immunstimulerende forbindelse
ATE260562T1 (de) Biozide zusammensetzungen umfassend ein aereogel enthaltend hydrophobes siliziumdioxid
NO20044916L (no) Preparater av sulfinylacetamid
IS7051A (is) Lyfjasamsetningar
NO20042636L (no) Soyamelk sammensetninger og fremgangsmater for fremstilling derav
NO20041968L (no) Anvendelse av cystationin
NO20035605D0 (no) Pediatrisk formulering av gatifloxacin
FR2822853B1 (fr) Preaparation de (mono) cristaux
DE60239734D1 (de) Herstellung von mikromechanischen siliziumstrukturen
NO20041485L (no) Farmasoytisk formulering omfattende (R)-bicalutamid
PT1392670E (pt) Derivados substituidos de c-furan-2-il-metilamina e c-tiofen-2-il-metilamina
NO20034351D0 (no) Optisk avbilding av endometrose
NO20035668D0 (no) Antitumorformuleringer av tioxantenon

Legal Events

Date Code Title Description
MK1K Patent expired